細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體
Monoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
- 編號UMAA788Hu24
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(克隆號)C4
- Ig亞型 IgG1 Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標記物無標記物
- 免疫原 RPA788Hu01-細胞程序性死亡蛋白1配體1(PDL1)重組蛋白
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 312 ¥ 729 ¥ 1041 ¥ 2603 ¥ 10410
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
IHC圖
-
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對PDL1的小鼠單克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別PDL1。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質期內，在適當?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| URPA788Hu02 | 細胞程序性死亡蛋白1配體1(PDL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA788Hu01 | 細胞程序性死亡蛋白1配體1(PDL1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA788Hu61 | 細胞程序性死亡蛋白1配體1(PDL1)活性蛋白 | Cell?culture;?Activity?Assays. |
| UEPA788Hu61 | 細胞程序性死亡蛋白1配體1(PDL1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA788Hu01 | 細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 | WB; ICC/IF |
| UFAA788Hu01 | 抗細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體 | Flow cytometry. |
| UFAA788Hu41 | 抗細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(藻紅素標記) | FCM |
| UFAA788Hu51 | 抗細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(別藻藍蛋白標記) | Flow cytometry. |
| UFAA788Hu81 | 抗細胞程序性死亡蛋白1配體1(PDL1)多克隆抗體(異硫氰酸熒光素標記) | Flow cytometry. |
| UMAA788Hu28 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | ICC/IF |
| UMAA788Hu22 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB. |
| URAA788Hu22 | 細胞程序性死亡蛋白1配體1(PDL1)重組抗體 | ICC/IF; FCM |
| UMAA788Hu21 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; ICC/IF |
| UMAA788Hu23 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; ICC/IF |
| UMAA788Hu24 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA788Hu25 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | ICC/IF |
| UMAA788Hu27 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB; IHC; ICC; IP. |
| UMAA788Hu29 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | ICC/IF |
| UMAA788Hu26 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體 | WB |
| URAA788Hu21 | 細胞程序性死亡蛋白1配體1(PDL1)重組抗體 | WB; ICC/IF; FCM |
| ULAA788Hu72 | 細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體(生物素標記) | WB |
| UFAA788Hu82 | 抗細胞程序性死亡蛋白1配體1(PDL1)單克隆抗體(異硫氰酸熒光素標記) | Flow cytometry. |
| UWEA788Hu | 細胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(酶聯(lián)免疫吸附試驗法,寬范圍) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USEA788Hu | 細胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA788Hu | 細胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA788Hu | 細胞程序性死亡蛋白1配體1(PDL1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UPSA788Hu01 | 細胞程序性死亡蛋白1配體1(PDL1)抗體對 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| UKSA788Hu01 | 細胞程序性死亡蛋白1配體1(PDL1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Chinese Journal of Cancer | Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742] |
| Leukemia.? | High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592] |
| Diabetes?Metab Res Rev. | PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853] |
| Lancet Haematol | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046] |
| Eur J Cancer.? | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170] |
| Journal of Cancer Research and Clinical Oncology | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007] |
| Journal of Hematology & Oncology | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703] |
| Lung Cancer. | High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990] |
| Oncotarget | Soluble?programmed?death-ligand?1?(sPDL1) and?neutrophil-to-lymphocyte?ratio?(NLR)?predictssurvival?in?advanced?biliary?tract?cancer?patients?treated?with palliative chemotherapy. [pubmed:27780932] |
| Oncotarget | High?post-treatment?serum?levels?of?soluble?programmed?cell?death?ligand?1?predict?earlyrelapse?and?poor?prognosis?in?extranodal?NK/T?cell?lymphoma patients. [pubmed:27105512] |
| Oncotarget.? | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569] |
| Cancer Immunol Immunother. | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165] |
| Leukemia | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525] |
| Allergology International? | Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514] |
| American Journal of Respiratory and Critical Care Medicine | Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164] |
| Clinical Lung Cancer | Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759] |
| Journal of Rheumatology | Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471] |
| Translational?Oncology | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935] |
| Immunology?Letters | Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals [Pubmed: 30236481] |
| Journal of?Cancer?Research?and?Clinical?Oncology | Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma [Pubmed: 30267213] |
| Annals?of?Surgical?Oncology | Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between?… [Pubmed: 30565045] |
| American Journal of Reproductive Immunology | Identification of programmed cell death 1 and its ligand in the testicular tissue of mice [Pubmed: 30578744] |
| PLoS?One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated?… [Pubmed: 30807610] |
| Endocrine Connections | Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer [Pubmed: 31252406] |
| Scientific Reports | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer [Pubmed: 31366979] |
| Critical Reviews in Oncology / Hematology | The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer [Pubmed: 31675543] |
| PLoS One | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer [Pubmed: 32176735] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
| Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma [Pubmed: 32054467] | |
| LIVER INTERNATIONAL | The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer [Pubmed: 32780918] |
| CANCER IMMUNOLOGY IMMUNOTHERAPY | Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients [Pubmed: 32577816] |
| Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure [Pubmed: 32443313] | |
| Cancer Immunol Immunother | The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte [33688997] |
| Acta Biochim Biophys Sin | Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management [34180502] |
| EMBO J | Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology [34825707] |
| Mol Pharm | A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors [34910492] |
| Mol Hum Reprod | Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis [Pubmed:35404426] |
| Journal of Nanobiotechnology | Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape [Pubmed:35705974] |
| Medicina | Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A?… [Pubmed:35208526] |
留言咨詢
